Puma Biotechnology Inc (PBYI) : Traders are bullish on Puma Biotechnology Inc (PBYI) as it has outperformed the S&P 500 by a wide margin of 21.16% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.42%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.95% in the last 1 week, and is up 18.71% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 2.56% and the 50-Day Moving Average is 22.81%.The 200 Day SMA reached 33.07% Puma Biotechnology, Inc. is up 90.45% in the last 3-month period. Year-to-Date the stock performance stands at -24.16%.
Puma Biotechnology Inc (PBYI) : The most positive equity analysts on Puma Biotechnology Inc (PBYI) expects the shares to touch $70, whereas, the least positive believes that the stock will trade at $36 in the short term. The company is covered by 4 Wall Street Brokerage Firms. The average price target for shares are $56.75 with an expected fluctuation of $14.55 from the mean.
For the current week, the company shares have a recommendation consensus of Buy. Puma Biotechnology Inc (NYSE:PBYI): stock was range-bound between the intraday low of $58.63 and the intraday high of $60.5 after having opened at $60.35 on Fridays session. The stock finally closed in the red at $60.35, a loss of -1.83%. The stock remained in the red for the whole trading day. The total traded volume was 1,439,413 shares. The stock failed to cross $60.5 in Fridays trading. The stocks closing price on Thursday was $59.46.
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the acquisition, development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It licenses the rights to three drug candidates. It is developing PB272 (neratinib (oral)) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation. It is developing PB272 (neratinib (intravenous)) for the treatment of patients with advanced cancer. PB357 is an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4.